Evidence map›Paper›PMID 41561105›Full record

ArticleERJ open research2026

Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis.

Jürgen Behr, Antje Prasse, Hubert Wirtz, Dirk Koschel, David Pittrow, Matthias Held, Jens Klotsche, Stefan Andreas, Martin Claussen, Christian Grohé and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Jürgen BehrDepartment of Medicine V, LMU University Hospital, LMU Munich, Munich, Germany.
Antje PrasseGerman Center for Lung Research (DZL), Munich, Germany.ORCID https://orcid.org/0000-0002-7336-7458
Hubert WirtzAbteilung für Pneumologie, Department Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig AöR, Leipzig, Germany.
Dirk KoschelLungenzentrum Coswig, Coswig, and Division of Pneumology, Medical Clinic 1, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
David PittrowInstitut für Klinische Pharmakologie, Medizinische Fakultät, Technische Universität Dresden, Dresden, Germany.ORCID https://orcid.org/0000-0003-1136-2616
Matthias HeldKlinikum Würzburg Mitte, Standort Missioklinik, Abteilung Innere Medizin, Pneumologie, Würzburg, Germany.
Jens KlotscheEpidemiologie, Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany.
Stefan AndreasLungenfachklinik Immenhausen und Universitätsmedizin Göttingen, Kardiologie und Pneumologie, Göttingen, Germany.ORCID https://orcid.org/0000-0003-3918-6909
Martin ClaussenGerman Center for Lung Research (DZL), Munich, Germany.
Christian GrohéKlinik für Pneumologie - ELK, Berlin Buch, Berlin, Germany.
Heinrike WilkensKlinik für Innere Medizin V, Pneumologie, Universitätsklinikum des Saarlandes, Homburg, Germany.
Lars HagmeyerKrankenhaus Bethanien, Klinik für Pneumologie und Allergologie, Zentrum für Schlaf- und Beatmungsmedizin, and Institut für Pneumologie, Universität zu Köln, Solingen, Germany.ORCID https://orcid.org/0000-0003-4285-1244
Dirk SkowaschDepartment of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn, Germany.
Joachim F MeyerLungenzentrum München, LZM Bogenhausen-Harlaching, Städtisches Klinikum München GmbH, München, Germany.
Joachim KirschnerCenter for Internal Medical Studies CIMS, Bamberg, Germany.
Sven GläserUniversitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B, Forschungsbereich Pneumologie und Pneumologische Epidemiologie, Greifswald, Germany.
Claus NeurohrKlinik Schillerhöhe, Abteilung für Pneumologie und Beatmungsmedizin, Geißlingen, Germany.
Martin SchwaiblmairDepartment of Internal Medicine I, University of Augsburg, Augsburg, Germany.
Katharina BuschulteGerman Center for Lung Research (DZL), Munich, Germany.
Tobias VeitDepartment of Medicine V, LMU University Hospital, LMU Munich, Munich, Germany.
Marion FrankenbergerComprehensive Pneumology Center, LMU University Hospital, LMU Munich, Germany.
Christopher J RyersonDepartment of Medicine, and Centre for Heart and Lung Innovation, University of British Columbia, Vancouver, BC, Canada.
Kerri A JohannsonDepartment of Medicine, University of Calgary, Calgary, AB, Canada.
Veronica MarcouxDepartment of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Jolene H FisherDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Deborah AssayagDepartment of Medicine, McGill University, Montreal, QC, Canada.ORCID https://orcid.org/0000-0002-2497-9984
Helene ManganasDépartement de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Nasreen KhalilDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Martin KolbDepartment of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.ORCID https://orcid.org/0000-0003-3837-1467
Michael KreuterMainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) has high morbidity and mortality with limited treatment options. Goal-oriented management approaches, such as the "treatable traits" concept, have yet to be implemented in IPF. This study aims to identify specific treatment goals in IPF for potential interventions by analysing outcomes from two national registries. Methods: We used data from the INSIGHTS-IPF registry, comprising 1232 IPF patients, enrolled from 2014 to 2020 as derivation cohort. Baseline and 6-month follow-up data were examined to assess clinical progression and predict 1-year mortality. Variables included forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide ( Results: Multivariable analysis identified FVC, Conclusion: This study provides a novel risk model for IPF patients, which may also apply to a broader spectrum of fibrotic ILD. It is based on potentially actionable variables which deserve further evaluation as measurable treatment goals in interventional clinical trials.

Identifiers

PMID41561105
PMCPMC12813680

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.